,2,6 SF mutations define clinical phenotypes in MDS to some extent, such as the strong association between SF3B1 mutations and the presence of ring sideroblasts,3,4 and have differing prognostic impacts.1 This evidence concerns the gene SF3B1 and myelodysplastic syndrome.